Raymond Comenzo, Boston, MA, USA
Isabel Krsnik, Madrid, Spain
OP21New organ response criteria for light chain amyloidosis: An international validation study
Eli Muchtar, Rochester, MN, USA
OP22The quest for indicators of profound hematologic response in AL amyloidosis: Complete response remains the optimal goal of therapy
Paolo Milani, Pavia, Italy
OP23Minimal residual disease positivity by multiparameter flow cytometry hinders organ involvement recovery in Al amyloidosis patients in complete response
Giovanni Palladini, Pavia, Italy
OP24In systemic light-chain amyloidosis the best hematologic response for long-term survival is IFLC < 10mg/L
Amandeep Godara, Boston, MA, USA
OP25Comparison of measures of complete hematologic response after high dose melphalan and autologous stem cell transplantation for AL amyloidosis
Shayna Sarosiek, Boston, MA, USA
OP26The impact and importance of post-renal transplantation haematological response assessment in AL amyloidosis
Oliver C. Cohen, London, UK
14:42 - 15:00Discussion
Hereditary ATTR Amyloidosis: Clinical Features and Follow-up
Rodney H. Falk, Boston, MA, USA
Lucía Galán, Madrid, Spain
Clinical features of polyneuropathy in hereditary amyloidosis
Yukio Ando, Kumamoto, Japan
Red-flags for early diagnosis in hereditary amyloidosis
Yoshiki Sekijima, Matsumoto, Japan
The global prevalence of ATTR amyloidosis
Hartmut Schmidt, Münster, Germany
Other manifestations in ATTR amyloidosis
Jonas Wixner, Umeå, Sweden
Follow-up, polyneuropathy detection, de novo manifestations and treatment after domino liver transplantation
Laura Obici, Pavia, Italy
16:00 – 16:20Discussion
Hereditary Transthyretin Amyloidosis
María Teresa Cibeira, Barcelona, Spain
Ole SuhrUmeå, Sweden
Multidisciplinary management and quality of life of patients with hereditary TTR amyloidosis with polyneuropathy
Violaine Planté-Bordeneuve, Créteil, France
Potential predictors of progression and response to treatment of hereditary TTR amyloidosis
Teresa Coelho, Porto, Portugal
Treatment of the polyneuropathy of hereditary TTR amyloidosis with antisense agents
Carlos Casasnovas, Barcelona, Spain
AA and other forms of Amyloidosis
Martha Skinner, Boston, MA, USA
Julian Gillmore, London, UK
AA amyloidosis: current incidence and clinical presentation
Alberto Martinez-Vea, Tarragona, Spain
AA amyloidosis: management
Luís Quintana, Barcelona, Spain
AA amyloidosis associated with autoinflammatory diseases
Helen Lachmann, London, UK
Localized amyloidosis
Eli Muchtar, Rochester, MN, USA
Hereditary non-transthyretin amyloidosis
Julian Gillmore, London, UK
LECT2-associated renal amyloidosis
Tamer Rezk, London, UK
19:10 - 19:30Discussion